These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27939305)

  • 41. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
    Davies MJ; Bain SC; Atkin SL; Rossing P; Scott D; Shamkhalova MS; Bosch-Traberg H; Syrén A; Umpierrez GE
    Diabetes Care; 2016 Feb; 39(2):222-30. PubMed ID: 26681713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
    Ponzani P; Corsi A
    Minerva Endocrinol; 2012 Mar; 37(1):1-8. PubMed ID: 22382611
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.
    Rizzo M; Rizvi AA; Patti AM; Nikolic D; Giglio RV; Castellino G; Li Volti G; Caprio M; Montalto G; Provenzano V; Genovese S; Ceriello A
    Cardiovasc Diabetol; 2016 Dec; 15(1):162. PubMed ID: 27912784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.
    Varanasi A; Patel P; Makdissi A; Dhindsa S; Chaudhuri A; Dandona P
    Endocr Pract; 2012; 18(2):140-5. PubMed ID: 21856595
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
    Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
    Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes.
    Dejgaard TF; Johansen NB; Frandsen CS; Asmar A; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Diabetes Obes Metab; 2017 May; 19(5):734-738. PubMed ID: 27935240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.
    Germain N; Khalfallah Y; Estour B; Galusca B
    Diabetes Res Clin Pract; 2018 Mar; 137():20-27. PubMed ID: 29253625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes.
    Overbeek JA; Heintjes EM; Huisman EL; Tikkanen CK; van Diermen AW; Penning-van Beest FJA; Herings RMC
    Diabetes Obes Metab; 2018 Sep; 20(9):2093-2102. PubMed ID: 29726082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
    Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
    J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
    van Velsen EF; Lamers J; Blok V; van Leendert RJ; Kiewiet-Kemper RM
    Neth J Med; 2014 Dec; 72(10):523-7. PubMed ID: 26219757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ADROPIN - POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE.
    Tičinović Kurir T; Miličević T; Novak A; Vilović M; Božić J
    Acta Clin Croat; 2020 Jun; 59(2):344-350. PubMed ID: 33456123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.
    Hiramatsu T; Asano Y; Mabuchi M; Imai K; Iguchi D; Furuta S
    Eur J Clin Invest; 2018 Oct; 48(10):e13007. PubMed ID: 30054920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
    Liou JH; Liu YM; Chen CH
    Transplant Proc; 2018 Oct; 50(8):2502-2505. PubMed ID: 30316386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
    Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
    Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.